信达生物全球首创双载荷ADC完成首例临床给药

DoNews
Yesterday

信达生物宣布,其自主研发的全球首创靶向CEACAM5的双载荷ADC(IBI3020)在I期临床研究中完成首例受试者给药。作为信达生物自研ADC平台DuetTx的首个双载荷ADC产品,IBI3020也是全球同类型双载荷ADC中首个进入临床阶段的项目。该研究旨在评估IBI3020在晚期实体瘤患者中的安全性、耐受性及初步有效性,并为II期临床试验确定推荐剂量。这一进展标志着信达生物在创新肿瘤疗法领域取得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10